ODTX Should I Buy

As previously reported, Wedbush initiated coverage of Odyssey Therapeutics with an Outperform rating and $30 price target. Odyssey's lead candidate OD-001 is an oral RIPK2 scaffolding inhibitor that has demonstrated monotherapy efficacy in ulcerative colitis, a large indication with a global estimated 2%-3% year-over-year growth rate, the firm notes. Phase 2 placebo-controlled monotherapy and Entyvio combination trials are planned to begin in the second half of 2026, with initial results expected in the second half of 2027. Preclinical development is underway for multiple additional candidates targeting various innate signaling nodes, offering pipeline diversification and upside potential, Wedbush argues. The firm holds a long-term favorable view of Odyssey given its novel approaches to target key signaling nodes, broad applicability of each pipeline candidate, and focus on I&I indications with large market potential.